Paper Details

  1. Home
  2. Paper Details

Mometasone furoate dry powder inhaler: a once-daily inhaled corticosteroid for the treatment of persistent asthma.

Author: KarpelJill P, NelsonHarold

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review found that mometasone furoate (MF) delivered by dry powder inhaler (MF-DPI) is effective in treating all severities of persistent asthma. Once-daily dosing of MF-DPI was effective in patients with mild or moderate persistent asthma previously taking twice-daily regimens of inhaled corticosteroids (ICSs), and in patients taking only inhaled beta2-agonists for symptom relief. Once-daily dosing in the evening with MF-DPI 200 microg conferred a greater benefit than morning dosing with MF-DPI 200 microg. In trials of up to 1 year in duration, MF-DPI was well tolerated, with the majority of adverse events considered mild or moderate in intensity.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Mometasone furoate (MF), a potent synthetic inhaled corticosteroid (ICS) with a high affinity for the glucocorticoid receptor, is approved for use in the treatment of asthma. SCOPE: Publications reviewed in this article were identified via searches of MEDLINE and EMBASE databases using ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1185/030079907x242485

データ提供：米国国立医学図書館（NLM）

Mometasone Furoate: A Breath of Fresh Air for Asthma Patients

Asthma, a chronic respiratory condition characterized by airway inflammation and bronchospasm, affects millions of people worldwide. This study explores the effectiveness of mometasone furoate (MF), a potent inhaled corticosteroid, in managing persistent asthma. The study reviews the results of clinical trials investigating the efficacy and safety of MF, delivered via a dry powder inhaler (MF-DPI), in patients with varying severities of asthma.

Mometasone Furoate: A Steady Breeze in the Storm of Asthma

The study demonstrates the effectiveness of MF-DPI in improving lung function, reducing asthma symptoms, and reducing or eliminating the need for oral corticosteroids in patients with persistent asthma. The study highlights the benefits of once-daily dosing with MF-DPI, particularly in the evening, which appears to offer greater efficacy compared to morning dosing. The study also confirms the safety of MF-DPI, demonstrating that it is well-tolerated with minimal systemic effects. It's like a gentle breeze in the midst of an asthma storm, offering relief and stability to patients struggling to breathe.

Mometasone Furoate: A Guiding Star in Asthma Management

This study provides valuable insights into the potential of MF-DPI as a safe and effective treatment for persistent asthma. It underscores the importance of individualized treatment approaches, considering factors such as asthma severity and the patient's response to treatment. The study also emphasizes the need for ongoing research to further explore the optimal dosing regimens and long-term implications of MF-DPI use. It's like a guiding star in the vast expanse of asthma management, illuminating the path towards improved health outcomes for patients.

Dr. Camel's Conclusion

This study provides a comprehensive overview of the efficacy and safety of mometasone furoate dry powder inhaler for treating persistent asthma. It highlights the potential of this medication to improve lung function, reduce asthma symptoms, and minimize the need for oral corticosteroids. It's like a refreshing oasis in the desert of asthma, providing relief from the symptoms and helping patients breathe easier.
Date :
  1. Date Completed 2008-01-16
  2. Date Revised 2019-09-11
Further Info :

Pubmed ID

17922978

DOI: Digital Object Identifier

10.1185/030079907x242485

Related Literature

Article Analysis
・Effects of mometasone oral inhalation
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.